Rigel Pharmaceuticals Inc (RIGL)

  • Get an in-depth profile of Rigel Pharmaceuticals Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
1.081 -0.009 (-0.87%)
Real-time Cboe USD Disclaimer

Rigel Pharmaceuticals Inc Company Profile

Industry
Biotechnology & Medical Research
Sector
Healthcare
Employees
165
Equity Type
ORD
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in discovering, developing and providing therapies that improve the lives of patients with hematologic disorders and cancer. The Company's lead product, TAVALISSE (fostamatinib disodium hexahydrate) tablets, the spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia (ITP). Its product also includes REZLIDHIA (olutasidenib) capsules, which are for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. Its other clinical programs include its interleukin receptor-associated kinase (IRAK) inhibitor program and a receptor-interacting serine/threonine-protein kinase (RIPK1) inhibitor program in clinical development. In addition, it has product candidates in clinical development with partners BerGenBio ASA (BerGenBio) and Daiichi Sankyo (Daiichi).
Contact Information
Address
South San Francisco,94080 United States
Phone
650 624 1100
Fax
650 624 1101
Web
https://www.rigel.com
Top Executives
Name
Age
Since
Title
Walter H. Moos 68 1997 Independent Director
Raul R. Rodriguez 62 2002 President, CEO & Director
Kamil Ali-Jackson 64 2021 Independent Director
Alison L. Hannah 62 2021 Independent Director
Gary A. Lyons 72 2005 Independent Director
Brian L. Kotzin 74 2017 Independent Director
Jane Wasman 67 2019 Independent Director
Gregory Anthony Lapointe 64 2017 Independent Chairman of the Board

Customize

Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles